Klaus Vedfelt/DigitalVision via Getty Images
- Amid the ebbs and flows of the stock market, SciSparc (NASDAQ:SPRC) witnessed a staggering 40% surge in post-market trading on a particularly eventful Friday. This surge was the result of the Israeli pharmaceutical company’s strategic decision to exclusively license its SCI-160 pain treatment program to Polyrizon.
- In a mutually beneficial move, Polyrizon secured an exclusive, royalty-bearing license to advance and sub-license the assets associated with the SCI-160 program. In exchange, SciSparc was promised $3M in Polyrizon securities, in addition to potential milestone fees amounting to approximately $3M along with ongoing royalties.
- Moreover, SciSparc disclosed that its top executives, including Chief Executive Officer and Chief Financial Officer Oz Adler, double as esteemed board members of Polyrizon, thereby cementing a collective strategic vision.
